UQ researchers have been awarded almost $1 million through the Australia-India Strategic Research Fund (AISRF) to combat the threat of antimicrobial resistance to human health.
Celldex reveals Phase 2 responses for chronic hives drug and higher rates of neutropenia
Celldex Therapeutics has unveiled 52-week results from a mid-stage study of its anti-KIT drug in chronic hives, raising anticipation for ongoing registrational studies. But the
September 26, 2024